{"id":41682,"date":"2025-09-17T14:30:25","date_gmt":"2025-09-17T06:30:25","guid":{"rendered":"https:\/\/flcube.com\/?p=41682"},"modified":"2025-09-17T14:30:25","modified_gmt":"2025-09-17T06:30:25","slug":"novo-nordisk-to-file-us-approval-for-high%e2%80%91dose-wegovy-aiming-to-match-lillys-zepbound","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41682","title":{"rendered":"Novo\u202fNordisk to File US Approval for High\u2011Dose Wegovy, Aiming to Match Lilly\u2019s Zepbound"},"content":{"rendered":"\n<p><strong>Novo Nordisk A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) has announced plans to seek U.S. regulatory approval for a high\u2011dose version of its weight\u2011loss injectable <strong>Wegovy (semaglutide)<\/strong>, a move that could intensify competition in the obesity market dominated by <strong>Eli\u202fLilly\u2019s Zepbound<\/strong>. The drugmaker first filed the high\u2011dose formulation in Europe earlier this year, and it is now preparing its Food and Drug Administration (FDA) application.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-key-points\">Key Points<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Product<\/strong> \u2013 High\u2011dose Wegovy delivers an increased semaglutide dose, expected to produce weight\u2011loss outcomes comparable to Lilly\u2019s Zepbound.<\/li>\n\n\n\n<li><strong>Strategic Rationale<\/strong> \u2013 By expanding its dosing range, Novo\u202fNordisk seeks to broaden its market share and offer clinicians a more potent option for patients who need greater weight reduction.<\/li>\n\n\n\n<li><strong>Regulatory Path<\/strong> \u2013 The company will file an Investigational New Drug (IND) application followed by a New Drug Application (NDA) with the FDA, mirroring the pathway used for its standard\u2011dose product.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obesity Treatment Landscape<\/strong> \u2013 The U.S. obesity market is projected to exceed $10\u202fbillion by 2028, driven by rising prevalence and increased payer coverage for pharmacologic therapies.<\/li>\n\n\n\n<li><strong>Competitive Dynamics<\/strong> \u2013 Eli\u202fLilly\u2019s Zepbound, approved in 2023, has quickly become a benchmark for high\u2011dose GLP\u20111 analogs, prompting rivals to accelerate their own high\u2011dose developments.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-executive-insight\">Executive Insight<\/h4>\n\n\n\n<p>Martin Holst Lange, Novo\u202fNordisk\u2019s Chief Scientific Officer, said at the European Association for the Study of Diabetes conference: \u201cHigh\u2011dose Wegovy offers the same weight\u2011loss potential as Lilly\u2019s Zepbound, giving patients another evidence\u2011based option.\u201d While the company has not yet formally announced its U.S. filing, the intent to proceed with FDA approval was made clear.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk A\/S (NYSE: NVO) has announced plans to seek U.S. regulatory approval for a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41684,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[199,38,148,860,86],"class_list":["post-41682","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-eli-lilly","tag-market-approval-filings","tag-novo-nordisk","tag-nyse-nvo","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo\u202fNordisk to File US Approval for High\u2011Dose Wegovy, Aiming to Match Lilly\u2019s Zepbound - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo\u202fNordisk A\/S (NYSE: NVO) has announced plans to seek U.S. regulatory approval for a high\u2011dose version of its weight\u2011loss injectable Wegovy (semaglutide), a move that could intensify competition in the obesity market dominated by Eli\u202fLilly\u2019s Zepbound. The drugmaker first filed the high\u2011dose formulation in Europe earlier this year, and it is now preparing its Food and Drug Administration (FDA) application.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41682\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo\u202fNordisk to File US Approval for High\u2011Dose Wegovy, Aiming to Match Lilly\u2019s Zepbound\" \/>\n<meta property=\"og:description\" content=\"Novo\u202fNordisk A\/S (NYSE: NVO) has announced plans to seek U.S. regulatory approval for a high\u2011dose version of its weight\u2011loss injectable Wegovy (semaglutide), a move that could intensify competition in the obesity market dominated by Eli\u202fLilly\u2019s Zepbound. The drugmaker first filed the high\u2011dose formulation in Europe earlier this year, and it is now preparing its Food and Drug Administration (FDA) application.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41682\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-17T06:30:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1705.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41682#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41682\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo\u202fNordisk to File US Approval for High\u2011Dose Wegovy, Aiming to Match Lilly\u2019s Zepbound\",\"datePublished\":\"2025-09-17T06:30:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41682\"},\"wordCount\":283,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41682#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1705.webp\",\"keywords\":[\"Eli Lilly\",\"Market approval filings\",\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41682#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41682\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41682\",\"name\":\"Novo\u202fNordisk to File US Approval for High\u2011Dose Wegovy, Aiming to Match Lilly\u2019s Zepbound - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41682#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41682#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1705.webp\",\"datePublished\":\"2025-09-17T06:30:25+00:00\",\"description\":\"Novo\u202fNordisk A\\\/S (NYSE: NVO) has announced plans to seek U.S. regulatory approval for a high\u2011dose version of its weight\u2011loss injectable Wegovy (semaglutide), a move that could intensify competition in the obesity market dominated by Eli\u202fLilly\u2019s Zepbound. The drugmaker first filed the high\u2011dose formulation in Europe earlier this year, and it is now preparing its Food and Drug Administration (FDA) application.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41682#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41682\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41682#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1705.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1705.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo\u202fNordisk to File US Approval for High\u2011Dose Wegovy, Aiming to Match Lilly\u2019s Zepbound\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41682#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo\u202fNordisk to File US Approval for High\u2011Dose Wegovy, Aiming to Match Lilly\u2019s Zepbound\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo\u202fNordisk to File US Approval for High\u2011Dose Wegovy, Aiming to Match Lilly\u2019s Zepbound - Insight, China&#039;s Pharmaceutical Industry","description":"Novo\u202fNordisk A\/S (NYSE: NVO) has announced plans to seek U.S. regulatory approval for a high\u2011dose version of its weight\u2011loss injectable Wegovy (semaglutide), a move that could intensify competition in the obesity market dominated by Eli\u202fLilly\u2019s Zepbound. The drugmaker first filed the high\u2011dose formulation in Europe earlier this year, and it is now preparing its Food and Drug Administration (FDA) application.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41682","og_locale":"en_US","og_type":"article","og_title":"Novo\u202fNordisk to File US Approval for High\u2011Dose Wegovy, Aiming to Match Lilly\u2019s Zepbound","og_description":"Novo\u202fNordisk A\/S (NYSE: NVO) has announced plans to seek U.S. regulatory approval for a high\u2011dose version of its weight\u2011loss injectable Wegovy (semaglutide), a move that could intensify competition in the obesity market dominated by Eli\u202fLilly\u2019s Zepbound. The drugmaker first filed the high\u2011dose formulation in Europe earlier this year, and it is now preparing its Food and Drug Administration (FDA) application.","og_url":"https:\/\/flcube.com\/?p=41682","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-17T06:30:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1705.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41682#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41682"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo\u202fNordisk to File US Approval for High\u2011Dose Wegovy, Aiming to Match Lilly\u2019s Zepbound","datePublished":"2025-09-17T06:30:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41682"},"wordCount":283,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41682#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1705.webp","keywords":["Eli Lilly","Market approval filings","Novo Nordisk","NYSE: NVO","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41682#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41682","url":"https:\/\/flcube.com\/?p=41682","name":"Novo\u202fNordisk to File US Approval for High\u2011Dose Wegovy, Aiming to Match Lilly\u2019s Zepbound - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41682#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41682#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1705.webp","datePublished":"2025-09-17T06:30:25+00:00","description":"Novo\u202fNordisk A\/S (NYSE: NVO) has announced plans to seek U.S. regulatory approval for a high\u2011dose version of its weight\u2011loss injectable Wegovy (semaglutide), a move that could intensify competition in the obesity market dominated by Eli\u202fLilly\u2019s Zepbound. The drugmaker first filed the high\u2011dose formulation in Europe earlier this year, and it is now preparing its Food and Drug Administration (FDA) application.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41682#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41682"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41682#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1705.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1705.webp","width":1080,"height":608,"caption":"Novo\u202fNordisk to File US Approval for High\u2011Dose Wegovy, Aiming to Match Lilly\u2019s Zepbound"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41682#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo\u202fNordisk to File US Approval for High\u2011Dose Wegovy, Aiming to Match Lilly\u2019s Zepbound"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1705.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41682"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41682\/revisions"}],"predecessor-version":[{"id":41685,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41682\/revisions\/41685"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41684"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}